X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs PANACEA BIOTECH - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD PANACEA BIOTECH MERCK LTD/
PANACEA BIOTECH
 
P/E (TTM) x 50.9 -21.1 - View Chart
P/BV x 7.7 2.5 308.0% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 MERCK LTD   PANACEA BIOTECH
EQUITY SHARE DATA
    MERCK LTD
Dec-16
PANACEA BIOTECH
Mar-14
MERCK LTD/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,060149 712.8%   
Low Rs62382 757.0%   
Sales per share (Unadj.) Rs632.484.1 751.6%  
Earnings per share (Unadj.) Rs45.7-18.3 -249.7%  
Cash flow per share (Unadj.) Rs62.3-6.7 -930.2%  
Dividends per share (Unadj.) Rs11.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs388.883.7 464.5%  
Shares outstanding (eoy) m16.6061.25 27.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.4 96.9%   
Avg P/E ratio x18.4-6.3 -291.8%  
P/CF ratio (eoy) x13.5-17.2 -78.3%  
Price / Book Value ratio x2.21.4 156.9%  
Dividend payout %24.10-   
Avg Mkt Cap Rs m13,9697,074 197.5%   
No. of employees `0001.62.8 57.6%   
Total wages/salary Rs m1,4871,449 102.6%   
Avg. sales/employee Rs Th6,631.91,874.1 353.9%   
Avg. wages/employee Rs Th939.2527.0 178.2%   
Avg. net profit/employee Rs Th479.4-407.7 -117.6%   
INCOME DATA
Net Sales Rs m10,4985,154 203.7%  
Other income Rs m242100 242.9%   
Total revenues Rs m10,7415,254 204.4%   
Gross profit Rs m1,135-766 -148.2%  
Depreciation Rs m276711 38.7%   
Interest Rs m01,503 0.0%   
Profit before tax Rs m1,102-2,881 -38.3%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m34317 2,043.5%   
Profit after tax Rs m759-1,121 -67.7%  
Gross profit margin %10.8-14.9 -72.7%  
Effective tax rate %31.1-0.6 -5,340.4%   
Net profit margin %7.2-21.8 -33.2%  
BALANCE SHEET DATA
Current assets Rs m6,4103,810 168.2%   
Current liabilities Rs m8,8288,365 105.5%   
Net working cap to sales %-23.0-88.4 26.1%  
Current ratio x0.70.5 159.4%  
Inventory Days Days58156 37.0%  
Debtors Days Days3867 57.1%  
Net fixed assets Rs m1,40614,480 9.7%   
Share capital Rs m16661 270.8%   
"Free" reserves Rs m6,286903 696.0%   
Net worth Rs m6,4555,127 125.9%   
Long term debt Rs m05,832 0.0%   
Total assets Rs m8,82819,433 45.4%  
Interest coverage xNM-0.9-  
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x1.20.3 448.4%   
Return on assets %8.62.0 437.7%  
Return on equity %11.8-21.9 -53.8%  
Return on capital %17.13.6 469.6%  
Exports to sales %8.324.5 33.8%   
Imports to sales %21.010.2 206.7%   
Exports (fob) Rs m8691,264 68.8%   
Imports (cif) Rs m2,209525 421.0%   
Fx inflow Rs m9591,539 62.3%   
Fx outflow Rs m2,612942 277.3%   
Net fx Rs m-1,653597 -276.8%   
CASH FLOW
From Operations Rs m1,070599 178.6%  
From Investments Rs m-750-438 171.2%  
From Financial Activity Rs m-150-303 49.5%  
Net Cashflow Rs m171-141 -120.9%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 0.6 3,033.3%  
FIIs % 1.0 1.3 76.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 23.6 123.3%  
Shareholders   28,591 10,259 278.7%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  UNICHEM LAB  ALKEM LABORATORIES  ELDER PHARMA  

Compare MERCK LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

MERCK LTD Announces Quarterly Results (4QFY18); Net Profit Up 53.2% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, MERCK LTD has posted a net profit of Rs 227 m (up 53.2% YoY). Sales on the other hand came in at Rs 3 bn (up 27.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Sep 21, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE MERCK LTD WITH

MARKET STATS